TOKYO, Feb 23 (Reuters) - Astellas Pharma Inc, Japan’s second-largest drugmaker, said on Monday it would continue to pursue U.S. biotech firm CV Therapeutics, which has rejected its $1 billion buyout offer.
TOKYO, Feb 23 (Reuters) - Astellas Pharma Inc, Japan’s second-largest drugmaker, said on Monday it would continue to pursue U.S. biotech firm CV Therapeutics, which has rejected its $1 billion buyout offer.
